PPARA and fatty liver disease: The impaired capacity of htgUGT1A-SNP mice to eliminate potential FXR or PPARα ligands may improve the PPARα-mediated mitochondrial fatty acid oxidation, hepatic fatty acid uptake, peroxisomal beta-oxidation or other crucial processes of lipid metabolism and leads to the lower degree of hepatic steatosis.